The Slump
Relaxo, the budget footwear leader, is having a rough year. Volume growth is negative for the third consecutive quarter, and management's guidance is cautious. The brand that became a household name on the back of value pricing in slippers and sandals is now being squeezed from two sides: mass-market consumers cutting back, and competitors absorbing the GST hike.
What's Going Wrong
Two factors stand out. First, mass-market consumer weakness,the segment Relaxo serves the most is the same one feeling food inflation and stagnant rural wages most acutely. Second, GST transitions on footwear created pricing turbulence that smaller competitors absorbed faster than Relaxo's larger SKU base could.
Relaxo built its dominance on price discipline. The same discipline now constrains it,every price action ripples across hundreds of SKUs and thousands of dealers. Smaller competitors can move faster.
, Datum Intelligence, FMCG Coverage
Margin Mix Tightens
Premium brands like Sparx and Flite are growing,that part of the portfolio is healthy. But premium can't carry the whole P&L when the mass-market core is shrinking. Bata India is also gaining ground in the mid-tier with newer styles, eating into Relaxo's premium-mass niche.
| Player | Segment | Volume growth | Share |
|---|---|---|---|
| Bata India | Premium-Mass | +6% | 22% |
| Relaxo | Mass-Market | -4% | 20% |
| Liberty | Mid-tier | +3% | 10% |
| Long tail | Mixed | +5% | 48% |
What's Next
Relaxo's path back is recovery in mass-market consumer demand and successful migration of the dealer network through the GST transition. Both are likely 12-18 months out. In the meantime, premium portfolio scale-up (Sparx in particular) buys time but doesn't replace mass-market volume. Investors should expect a tepid run until at least H2 FY26 before underlying volume momentum resumes.
Source: Company filings, Datum Intelligence analysis. For informational purposes only.